Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00657254 · ClinicalTrials.gov registry record · Phase 2
Extension Program for Bay 43-9006
A Phase 2 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT00657254 is a Phase 2 study that has completed, run by Bayer. The registered enrollment target is 9 participants.
The verdict
NCT00657254, a Phase 2 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The study was designed to allow for the continuation of treatment with Sorafenib as a single agent to those patients who participated in a previous Sorafenib study that had reached its designated end-date and who were, in the opinion of the Investigator and the Sponsor, still benefiting from treatment.
Interventions
- DRUG Nexavar (Sorafenib, BAY43-9006)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2002-12 |
| Est. Completion | 2005-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00657254
The ClinicalTrials.gov registry entry for NCT00657254 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nexavar (Sorafenib, BAY43-9006) is the first listed.
NCT00657254 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00657254 about?
NCT00657254 is a clinical study titled "Extension Program for Bay 43-9006". The study was designed to allow for the continuation of treatment with Sorafenib as a single agent to those patients who participated in a previous Sorafenib study that had reached its designated end-date and who were, in the opinion of the Investigator and the Sponsor, still benefiting from treatme...
What is the current status of trial NCT00657254?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2002-12. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00657254?
The interventions under investigation include: Nexavar (Sorafenib, BAY43-9006) (DRUG).
Who is sponsoring clinical trial NCT00657254?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.